Maintenance6 min read

Life after a GLP-1: maintenance and avoiding regain

Reaching a goal weight is a milestone worth celebrating — and the start of a new chapter, not the end of the story. Understanding what happens next makes maintenance far less daunting.

GLP-1s manage weight — they don't cure it

Obesity is increasingly understood as a chronic, relapsing condition. GLP-1 medications treat it effectively while they're taken, much as blood-pressure medication works while it's taken.

That framing matters: it isn't a moral question or a willpower question. It's a medical one.

What the STEP 4 trial showed

In the STEP 4 trial, people who had lost weight on semaglutide and then switched to placebo regained a substantial portion of it, while those who continued the medication largely held their loss.

Stopping a GLP-1 is a real decision with real consequences — and one to make with a prescriber, not alone.

Maintenance is a phase, not a finish line

Whether you stay on the medication, taper, or stop, maintenance is its own skill. The job changes from 'lose more' to 'hold steady within a range' — and that range, not a single number, is the realistic target.

Trimm's maintenance mode is built for exactly this: it watches a band you choose and flags drift early, before it becomes regain.

The habits that carry you

The behaviours that protect a maintained weight are the ones worth building during the losing phase, so they're already automatic:

Enough protein, and regular resistance training to keep muscle.
Consistent logging — so drift is caught in weeks, not months.
A maintenance weight range rather than a single goal number.
Regular check-ins with your prescriber about the long-term plan.

The short version

Obesity is a chronic condition; GLP-1s manage it while taken.
STEP 4 showed meaningful regain after stopping semaglutide.
Maintenance is an active phase — aim for a range, not a number.
Build protein, strength, and logging habits before you need them.

Sources

1.Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA (2021).The STEP 4 trial — weight regain after switching from semaglutide to placebo.
2.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism (2018).

This is general education, not medical advice. It can't account for your individual history — decisions about your medication, dose, and care belong with you and your prescriber.